These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 20970245)
1. Is tumor response important for renal carcinoma? Inman BA; George DJ Eur Urol; 2011 Jan; 59(1):16-7. PubMed ID: 20970245 [No Abstract] [Full Text] [Related]
2. Re: E. Jason Abel, Stephen H. Culp, Nizar M. Tannir, et al. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol 2011;59:10-5. Ozcan MF; Canda AE; Dizdar O; Altinova S; Akbulut Z; Balbay MD Eur Urol; 2011 Jun; 59(6):e34. PubMed ID: 21398023 [No Abstract] [Full Text] [Related]
3. Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials. Bex A; Jonasch E; Kirkali Z; Mejean A; Mulders P; Oudard S; Patard JJ; Powles T; van Poppel H; Wood CG Eur Urol; 2010 Dec; 58(6):819-28. PubMed ID: 20828919 [TBL] [Abstract][Full Text] [Related]
9. Editorial comment on: external validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology. Blute ML Eur Urol; 2010 Jan; 57(1):110-1. PubMed ID: 19062158 [No Abstract] [Full Text] [Related]
10. Editorial comment on: External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology. Giannarini G; Autorino R Eur Urol; 2010 Jan; 57(1):109-10. PubMed ID: 19062156 [No Abstract] [Full Text] [Related]
11. The role of cytoreductive nephrectomy in the era of molecular targeted therapy. Polcari AJ; Gorbonos A; Milner JE; Flanigan RC Int J Urol; 2009 Mar; 16(3):227-33. PubMed ID: 19207114 [TBL] [Abstract][Full Text] [Related]
12. Targeted therapies and survival: what we can learn from studies in advanced renal cell carcinoma. Procopio G; Verzoni E; de Braud F Oncology; 2013; 84(1):39-42. PubMed ID: 23076302 [No Abstract] [Full Text] [Related]
13. [Molecular targeted therapy for advanced renal cell carcinoma]. Kanayama H Gan To Kagaku Ryoho; 2010 Jul; 37(7):1208-13. PubMed ID: 20647700 [TBL] [Abstract][Full Text] [Related]
15. Temsirolimus (Torisel) for advanced renal cell carcinoma. Med Lett Drugs Ther; 2007 Dec; 49(1276):103-4. PubMed ID: 18084154 [No Abstract] [Full Text] [Related]
16. Retrospective analyses of patient characteristics having predictive impact on survival under everolimus. Seidel C; Fenner M; Reuter C; Merseburger AS; Ganser A; Grünwald V Onkologie; 2011; 34(3):111-4. PubMed ID: 21358215 [TBL] [Abstract][Full Text] [Related]
17. Editorial comment on: Vaccine therapy in patients with renal cell carcinoma. Bellmunt J; Ribas A Eur Urol; 2009 Jun; 55(6):1342-3. PubMed ID: 19201525 [No Abstract] [Full Text] [Related]
18. Editorial comment on: Vaccine therapy in patients with renal cell carcinoma. Clark PE Eur Urol; 2009 Jun; 55(6):1343-4. PubMed ID: 19201523 [No Abstract] [Full Text] [Related]
19. [Drug now immediately available in Germany]. Aktuelle Urol; 2006 Sep; 37(5 Suppl):18-9. PubMed ID: 23646396 [No Abstract] [Full Text] [Related]